Last Updated：2025/11/20
The clinical trial evaluated the safety and tumor-targeting efficacy of 90Y-DOTA-biotin in patients with recurrent ovarian cancer.
See correct answer
The clinical trial evaluated the safety and tumor-targeting efficacy of 90Y-DOTA-biotin in patients with recurrent ovarian cancer.
音声機能が動作しない場合はこちらをご確認ください
Edit Histories（0）
